A
Armando Santoro
Researcher at Humanitas University
Publications - 961
Citations - 56759
Armando Santoro is an academic researcher from Humanitas University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 93, co-authored 847 publications receiving 48505 citations. Previous affiliations of Armando Santoro include Aix-Marseille University & University of Milan.
Papers
More filters
Journal ArticleDOI
Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System
M.G. Della Porta,Christopher Jackson,Emilio Paolo Alessandrino,Marianna Rossi,Andrea Bacigalupo,M. T. Van Lint,Massimo Bernardi,Bernardino Allione,Alberto Bosi,Stefano Guidi,Valeria Santini,Luca Malcovati,Marta Ubezio,Chiara Milanesi,Elisabetta Todisco,Maria Teresa Voso,Pellegrino Musto,Francesco Onida,A. P. Iori,Raffaella Cerretti,Giovanni Grillo,Alfredo Molteni,Pietro Pioltelli,Lorenza Borin,Emanuele Angelucci,Elena Oldani,Simona Sica,Cristiana Pascutto,Virginia Valeria Ferretti,Armando Santoro,Francesca Bonifazi,Mario Cazzola,Alessandro Rambaldi +32 more
TL;DR: A decision analysis on 1728 patients with myelodysplastic syndrome who received supportive care, transplantation or hypomethylating agents (HMAs) provides a preliminary evidence to maximize the effectiveness of allo-SCT in MDS.
Journal ArticleDOI
Clinical significance of neuroendocrine phenotype in non-small-cell lung cancer
TL;DR: There is no doubt that caution is required when interpreting the results of a number of studies questioning the clinical impact of the NE features of NSCLCs, as there is no gold standard defining NE differentiation.
Journal ArticleDOI
Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma: A phase II randomized study
Carlo Tondini,Monica Balzarotti,I. Rampinelli,P. Valagussa,M Luoni,A. De Paoli,Armando Santoro,G. Bonadonna +7 more
TL;DR: This study confirms that Flu and CdA have similar response rates and durations, however, further studies are required to optimize the C dA schedule and dosage in order to ameliorate its toxic profile while maintaining antitumor activity.
Journal ArticleDOI
Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomas
Luca Castagna,S Bramanti,S. Furst,Laura Giordano,Roberto Crocchiolo,Barbara Sarina,Elisa Mauro,Lucio Morabito,R. Bouabdallah,Diane Coso,Monica Balzarotti,F Broussais,Jean El-Cheikh,C C Stella,Ercole Brusamolino,Didier Blaise,Armando Santoro +16 more
TL;DR: T-repleted Haploidentical transplantation with post-infusion CY is a feasible and effective therapy in the poor prognosis of advanced lymphoma patients.
Journal ArticleDOI
Reproducibility of the WHO classification of thymomas: Practical implications
Paolo Andrea Zucali,L. Di Tommaso,Iacopo Petrini,Serena Battista,Hye Seung Lee,Maria J. Merino,Elena Lorenzi,Emanuele Voulaz,F. De Vincenzo,Matteo Simonelli,Massimo Roncalli,Laura Giordano,Marco Alloisio,Armando Santoro,G. Giaccone +14 more
TL;DR: The agreement on WHO classification of thymomas was only moderate and this impacted on patients management and the histotype showed a statistically significant impact on PFS and DRS in the classification provided by only two pathologists.